10-Q: Harrow Inc. Reports Q2 2026 Results: Revenue Up, Losses Widen

Harrow Inc. announced its Q2 2026 financial results, showing an increase in total revenues driven by its branded segment, but also reporting a significant net loss and increased operating expenses.

Summary

• Harrow Inc. reported total revenues of $70.7 million for the three months ended June 30, 2026, an increase from $63.7 million in the prior year period.
• For the six months ended June 30, 2026, total revenues were $114.9 million, up from $111.6 million in the same period last year.
• The company incurred a net loss of $17.3 million for the three months ended June 30, 2026, compared to a net income of $5.0 million in the prior year.
• The net loss for the six months ended June 30, 2026, was $44.9 million, a significant increase from a net loss of $12.8 million in the prior year.
• Selling, general, and administrative expenses increased by $20.1 million to $53.3 million for the three months ended June 30, 2026.
• Research and development expenses rose by $5.2 million to $8.1 million for the three months ended June 30, 2026.
• The company's cash and cash equivalents increased to $83.9 million as of June 30, 2026, from $72.9 million at the end of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, increased operating expenses, and a decline in gross margin for the compounding segment, despite revenue growth in the branded segment.

Positives

• Total revenues increased by $6.9 million to $70.7 million for the three months ended June 30, 2026, driven by growth in the branded segment.
• Branded revenue increased by $13.8 million to $56.1 million for the three months ended June 30, 2026.
• VEVYE sales showed significant growth, increasing by $10.7 million to $29.4 million for the three months ended June 30, 2026.
• Cash and cash equivalents increased to $83.9 million as of June 30, 2026, providing a healthy liquidity position.
• The company has entered into an agreement to acquire global rights to TYRVAYA, a treatment for dry eye disease, for $30 million plus potential milestones.

Negatives

• The company reported a net loss of $17.3 million for the three months ended June 30, 2026, a significant deterioration from a net income of $5.0 million in the prior year.
• The net loss for the six months ended June 30, 2026, widened to $44.9 million from $12.8 million in the prior year.
• Gross margin for the branded segment decreased by 3.2% to 76.1% for the three months ended June 30, 2026.
• Gross margin for the compounding segment significantly decreased by 12.3% to 52.8% for the three months ended June 30, 2026.
• Selling, general, and administrative expenses increased by $20.1 million to $53.3 million for the three months ended June 30, 2026.
• Research and development expenses increased by $5.2 million to $8.1 million for the three months ended June 30, 2026.
• Compounding revenue decreased by $6.9 million to $14.6 million for the three months ended June 30, 2026.

Risks

• Sales depend on coverage and reimbursement from government and commercial third-party payors, and pricing and reimbursement pressures could adversely affect profitability.
• The company's reported revenues depend on significant estimates of variable consideration, including rebates and chargebacks, which may differ from actual results.
• The company is involved in various legal proceedings, including a significant judgment against OSRX, the outcome of which is uncertain and could materially affect financial results.
• The company may not be able to obtain necessary financing to support its business plan, which could require modification of operations or discontinuation of operations.
• The acquisition of TYRVAYA involves contingent milestone payments, the achievement of which depends on future sales performance.
• The company relies on three main suppliers for active pharmaceutical ingredients, which could pose a supply chain risk.

Future Outlook

The company believes its current cash position is sufficient to sustain planned operations, capital expenditures, and acquisitions for at least the next 12 months. It may consider asset sales and is pursuing the acquisition of TYRVAYA. Future cash needs are expected to be met by operating activities, but additional financing may be sought through various sources if needed.

Management Comments

• The company believes it has built a tangible and intangible infrastructure that will allow it to scale revenues efficiently in the near and long-term.
• The company expects to fund the cash payment for the TYRVAYA acquisition with cash on hand.

Industry Context

StockSavvy.ai notes that Harrow operates in the competitive eyecare pharmaceutical market, facing pressures from payors and regulatory bodies. The acquisition of TYRVAYA indicates a strategic move to expand its portfolio in the dry eye disease segment, a growing area within ophthalmology.

Comparison to Industry Standards

• The filing does not provide direct comparisons to industry benchmarks or specific competitor financial results.
• The company's gross margin for its branded segment (71.9% YTD 2026) is generally strong, but the decline from the prior year warrants monitoring.
• The compounding segment's gross margin (53.4% YTD 2026) is significantly lower than the branded segment, reflecting different business models and cost structures.
• The increase in SG&A expenses as a percentage of revenue for the branded segment suggests investment in growth, which is common in the pharmaceutical industry, but the overall net loss is a concern.

Legal Proceedings

• ImprimisRx, LLC (a subsidiary) filed a lawsuit against Ocular Science, Inc. and OSRX, Inc. for copyright infringement, trademark infringement, unfair competition, and false advertising. A jury awarded $34.9 million, which was later reduced to $11.2 million plus interest. OSRX has filed an appeal, and no collection activity is allowed during the appeal.

Stakeholder Impact

• Shareholders may experience dilution if the company issues equity to raise additional funds.
• Creditors' risk may increase if the company takes on additional debt, increasing leverage.
• Customers and end-users may benefit from the company's efforts to make products accessible and affordable.
• Suppliers may be impacted by the company's procurement strategies and potential growth or contraction.

Next Steps

• Complete the acquisition of TYRVAYA from Viatris Inc.
• Continue to develop and commercialize drug candidates, compounded formulations, and technologies.
• Integrate and develop operations.
• Pursue potential future strategic transactions, including acquisitions.
• Conduct clinical trials or other studies for FDA approval.
• Fund operations and planned capital expenditures.

Key Dates

Recommendation

The significant increase in net losses, widening deficit, and declining gross margins, particularly in the compounding segment, coupled with increased operating expenses, suggest a deteriorating financial performance. While revenue growth in the branded segment and the planned acquisition of TYRVAYA offer some potential, the current financial trajectory and increased debt levels present considerable risk.

Keywords

eyecare, ophthalmic pharmaceutical, branded products, compounding pharmacy, revenue, net loss, operating expenses, TYRVAYA acquisition